AIC
REGN icon

Argus Investors Counsel’s Regeneron Pharmaceuticals REGN Stock Holding History

Argus Investors Counsel’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,820
Closed -$1.3M – 120
2024
Q4 		$1.3M Sell
1,820
-21
-1% -$17.6K 0.87% 36
2024
Q3 		$1.94M Buy
1,841
+290
+19% +$323K 1.26% 27
2024
Q2 		$1.63M Buy
1,551
+86
+6% +$83.4K 1% 31
2024
Q1 		$1.41M Buy
+1,465
New +$1.39M 0.87% 52

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Argus Investors Counsel's REGN Position: Q1 2025 in Review

Argus Investors Counsel sold out of Regeneron Pharmaceuticals (REGN) in Q1 2025, closing a stake of 1,820 shares — an estimated $1.3M sold.

Argus Investors Counsel first reported a position in REGN in Q1 2024 and held it in 4 quarters. The position peaked at $1.94M in Q3 2024. 1,291 funds tracked by Wall St. Rank hold REGN as of Q1 2025.

  • Argus Investors Counsel reported no remaining Regeneron Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Argus Investors Counsel sold 1,820 Regeneron Pharmaceuticals shares in Q1 2025, an estimated $1.3M.
  • Argus Investors Counsel first reported a position in Regeneron Pharmaceuticals in Q1 2024 and held it in 4 quarters.
  • Argus Investors Counsel's Regeneron Pharmaceuticals position peaked at $1.94M in Q3 2024.
  • 1,291 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2025.

Based on Argus Investors Counsel's 13F filing for Q1 2025, filed 16 Apr 2025.